高精度放疗在儿童颅咽管瘤中获得了良好的长期控制和保留功能——一项随机试验的亚群分析。

IF 13.4 1区 医学 Q1 CLINICAL NEUROLOGY
Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda
{"title":"高精度放疗在儿童颅咽管瘤中获得了良好的长期控制和保留功能——一项随机试验的亚群分析。","authors":"Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda","doi":"10.1093/neuonc/noaf049","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).</p><p><strong>Methods: </strong>Eighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.</p><p><strong>Results: </strong>The median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).</p><p><strong>Conclusions: </strong>SCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2147-2157"},"PeriodicalIF":13.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448793/pdf/","citationCount":"0","resultStr":"{\"title\":\"High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.\",\"authors\":\"Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda\",\"doi\":\"10.1093/neuonc/noaf049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).</p><p><strong>Methods: </strong>Eighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.</p><p><strong>Results: </strong>The median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).</p><p><strong>Conclusions: </strong>SCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.</p>\",\"PeriodicalId\":19377,\"journal\":{\"name\":\"Neuro-oncology\",\"volume\":\" \",\"pages\":\"2147-2157\"},\"PeriodicalIF\":13.4000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448793/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/neuonc/noaf049\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noaf049","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:儿童和青少年颅咽管瘤(CP)不断发展的治疗模式旨在减少晚期功能后遗症。先进的放射治疗技术提供了保留神经功能的理论优势,然而,临床证据是有限的。目前的研究是在一项随机对照试验中对CP患者进行常规放射治疗(ConvRT)和立体定向适形放射治疗(SCRT)(NCT00517959)的二次分析。方法:对82例CP患者(SCRT: 39例,ConvRT: 43例,剂量:54Gy, 30份)进行分析,评估剂量节约对神经认知功能、内分泌功能、总生存期(OS)和局部控制(LC)的临床影响。使用WISC/WAIS量表从基线到治疗后5年对患者进行纵向评估。结果:中位年龄13岁(IQR= 9 ~ 17岁)。10年OS和LC率分别为86.4%和92.7%,两组间无显著差异。SCRT患者的平均全量表智商(斜率差=3.3分/年,p= 0.01)和表现商(斜率差=3.6分,p= 0.04)较ConvRT组有显著改善。SCRT组5年时认知能力下降(下降5个点)的自由度更高(66.6% vs. 38.2%;HR = 0.41, p = 0.03)。结论:与常规RT相比,SCRT在CP患者中具有良好的肿瘤控制和相似的生存期,并具有优越的神经认知和内分泌功能的长期保存。高精度RT应成为CP的护理标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.

Background: The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).

Methods: Eighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.

Results: The median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).

Conclusions: SCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信